Ethic committee from UNIFESP: number 1573/08.
INTRODUCTION
Nitric Oxide (NO) is a signaling molecule responsible for several physiological and pathophysiological actions throughout the human body, including blood flow control and modulation of immune res ponse (1, 2) . In mammals, NO is considered to circulate as S-nitrosothiols, mainly S-nitrosoglutathione (GSNO), S-nitrosoalbumin and pos sibly S-nitrosohemoglobin (3, 4) . Synthetic GSNO and S-nitroso-Nace tylcysteine (SNAC) were already used as exogenous NO donors in different experimental settings (5, 6) . In the eye, NO has been shown to be a key regulator of vascular tone in ophthalmic arteries (7, 8) and animal and human studies have demonstrated reduction in the choroidal blood flow with systemic infusion of NO inhibitors (9) (10) (11) . NO donors were also shown to increase blood flow in the retina, choroid and the optic nerve head (12, 13) . Additionally, some studies have addressed the beneficial effect of S-nitrosothiols on the reduction of intraocular pressure (14) (15) (16) (17) , and suggest that S-nitrosothiols are potential new drugs for the treatment of glaucoma and other ocular ischemic diseases (13) . Nitric oxide-mediated antimicrobial activity has also been the fo cus of recent research (18, 19) . GSNO and SNAC displayed bactericidal and bac teriostatic activities against several Gram-positive and Gram-negative clinical isolates from patients with bacterial infectious keratitis (20) . In addition, GSNO and SNAC were also shown to exert potent antimicrobial actions against trophozoites of Acanthamoe ba castellanii, the etiological agent responsible for a devastating si ght-threatening keratitis (21) . These data suggest that NO donors are important candidates for treating infectious eye diseases. Other possible therapeutic applications of S-nitrosothiols in ophthalmology include corneal wound healing (22) , antifibrotic effect in glaucoma filtering surgery (23) and anti-inflammatory action in autoimmune uveitis (24) . Despite these potential clinical applications of S-nitrosothiols in ophthalmology, the ocular toxicity of these compounds is not yet known. The purpose of the present study was to evaluate the ocular surface toxicity of GSNO and SNAC after topical installations in ex vivo and in vivo animal models.
RESUMO

METHODS
Materials
Glutathione (g-Glu-Cys-Glu, GSH), N-acetyl-cysteine (NAC), sodium nitrite (NaNO2), hydrochloric acid (HCl), phosphate buffer saline solution, pH 7.4 (PBS) and acetone were purchased from Sigma (St. Louis, MO, USA) and used as received. Ketamine and xylazine hydrochlorides were purchased from Phoenix Scientific Inc. (St. Joseph, MO, USA). Hydroxypropyl methylcellulose (HPMC) was manufactured by Dow Chemical Company (Midland, MI, USA).
synthesis of Gsno and snaC
GSNO and SNAC were synthesized as previously described (25) . SNAC solutions were prepared from a freshly made stock solution 40.0 mM and further diluted in PBS to 2.0 and 20.0 mM with a final pH 7.0. GSNO solutions 2.0 and 20.0 mM, pH 7.0, were prepared immediately before use from solid GSNO.
PreParation of s-nitrosothiols-ContaininG hPMC forMulations
SNAC and GSNO concentrations 1.0 and 10.0 mM in HPMC solution 2% (w/v) were prepared by mixing equal volumes of aqueous HPMC solution 4% (w/v) and SNAC or GSNO solutions 2.0 or 20.0 mM, prepared as above, under stirring. These formulations were designated as SNAC 1, SNAC 10, GSNO 1 and GSNO 10, respectively.
stability of the hPMC-ContaininG s-nitrosothiols forMulations
The concentrations of SNAC and GSNO in the HPMC formulations were spectrophotometrically monitored during their storage in the dark at 37ºC for 1 h, based on their characteristic optical absorption bands at 336 nm, assigned to the -SNO moiety. A Diode-array spectrophotometer (HP-8453, Hewlett-Packard, Palo Alto, CA, USA) was used for this purpose. GSNO and SNAC solutions 10 mmol L -1 were monitored over 1 h in a 1 cm optical path quartz cuvette. Concentration changes in the solutions were calculated based on the molar absorption coefficient of GSNO and SNAC (900.0 mol -1 L cm -1 at 336 nm).
aniMals
Male New Zealand healthy albino rabbits (1.8 to 2.2 kg) were purchased from the Center of Development of Experimental Models for Medicine and Biology (CEDEME, São Paulo, Brazil). All animals were handled in accordance with the NIH Principles of laboratory animal care and the ARVO statement for the use of animals in ophthalmic and vision research. The experimental protocol was previously approved by the Research Ethics Committee from Federal University of São Paulo. All animals were acclimated and housed in individual cages (designed to avoid accidental injury) and kept in a room with 12-h light-dark diurnal cycle, adequate air turnover and constant temperature (22°C), receiving standard rabbit chow (Purina, São Paulo, Brazil) and water ad libitum. All procedures were performed under systemic anesthesia with intramuscular injection of 30 mg/kg of ketamine hydrochloride and 5 mg/kg of xylazine hydrochloride.
Ex vivo evaluation
For ethical reasons, the toxicities of the S-nitrosothiols formulations were previously evaluated in an ex vivo model to lessen the likelihood of any non-selective effects in rabbit eyes during the in vivo tests. Twenty-five freshly excised pig eyeballs were obtained from a local slaughterhouse immediately after slaughter, washed thoroughly with PBS and divided into five groups. The eyeballs of each of four experimental groups were instilled with 500 μL of SNAC 1, SNAC 10, GSNO 1 or GSNO 10 formulations onto the cornea and conjunctiva.
The fifth group received the same volume of pure HPMC solution 2% (w/v) and served as a control. The eyeballs were clinically analyzed under a surgical microscope before instillation and 30 min and 1 h after instillation. The eyeballs were fixed in 10% formalin solution for 48 h, stained with hematoxylin-eosin and subjected to histological analysis.
oCular tolerability
Twenty rabbits were randomized into 4 groups with 5 animals each: groups 1 and 2 received instillations of 150 mL of GSNO 1 and GSNO 10, respectively, in one eye (randomly chosen by coin toss between right or left side); groups 3 and 4 received 150 mL of SNAC 1 and SNAC 10, respectively, in one eye (randomly chosen as above). The contralateral eye of each animal received aqueous HPMC as a control. A sentinel study with a single animal per group was performed before the entire experiment and showed no clinical and histological damage up to 72 h. Based on this result, the evaluation of toxicity was limited to 24 h.
A modified Draize test was used to access potential ocular irritancy (26) . Slit lamp examination was performed before drug exposure to ensure normal ocular surface integrity and repeated 1 and 24 h after drug instillation. The score system evaluated the corneal opacity (scored from 0 to 4), iritis (from 0 to 2) and conjunctival redness (from 0 to 3) (26) . The final score was calculated by summing the cornea, iris and conjunctiva scores, which ranged from 0 to 9. The score criteria were defined according to the following cutoffs: under 1: non-ir ritating; 1 to 4: mildly irritating; 5 to 7: moderately irritating; over 7: severely irritating.
After 24 h all animals were sacrificed with intravenous pentobarbital sodium injection under anesthesia, the eyes were enucleated, fixed in 10% formalin solution for 48 h and then histologically analyzed (hematoxylin-eosin stain). All the slit lamp evaluations were performed under double blind conditions (i.e. both the investigator who performed the instillations and the investigator who performed the histological analysis did not know the formulation identity).
statistiCal analyses
Data were expressed as mean ± standard deviation. The comparisons between Draize score of control and treated eyes were done using the non-parametric Mann-Whitney U test. P values <0.05 indicated statistical significance.
RESULTS
In the ex vivo experiment, all pig eyes showed no signs of perforation, tissue erosion, corneal opacity or other gross damage. The conjunctival and corneal epithelium were preserved and there was no significant difference between treated and control groups. Histological evaluation confirmed the absence of damage in the pig conjunctival and corneal epithelium and the preservation of external and intraocular tissue structures in the treated groups.
In the in vivo experiments, all formulations showed a mean score under 1 and were classified as "non-irritating" compounds. None of the animals developed corneal opacity or iritis. There was no significant difference in the mean score between control and the treated groups 1 and 24 h after drug instillation (p>0.05) ( Table 1 ). The animal blink rate or eye wiping 5 min into the recovery period after anesthesia were unaffected by drug treatment.
The palpebral, cul-de-sac and bulbar conjunctival histologies of all control and treated animals were unchanged. No vessel proliferation or immune cell infiltration was detected. The Goblet-cells were present throughout the entire conjunctival surface with no cytoarchitectural modifications. The limbus was preserved and no inflammatory cell infiltration was noted. The cornea also had an unchanged appearance in all its layers with no angiogenesis or inflammatory signs (Figure 1 ). No histological modifications were noted in the sclera, iris, lens, choroid and retina.
Evaluation of the stability of the SNAC 10 and GSNO 10 formulations at 37ºC showed that less than 2% of the SNAC or GSNO decompose under this condition after 1 h.
DISCUSSION
In spite of their potential therapeutic applications, the ocular toxicity of GSNO and SNAC had not been characterized yet. Previous studies performed to evaluate the ocular hypotensive effect of other topical NO donors, like sodium nitroprusside and S-nitroso-N-acetyl-DL-penicillamine reported no adverse effects in the concentration range 1-2 mM (14, 15) . Equimolar concentrations of different NO donors lead to variable levels of detectable NO metabolites in vitro and in vivo and differences in pharmacological and pharmacokinetic properties of these compounds can lead to different clinical effects in ocular tissues (15) . Thus, results obtained with a specific nitric oxide donor cannot always be extended to S-nitrosothiols such as GSNO and SNAC. This was the first standardized study to evaluate the potential toxic effects of topical instillation of aqueous HPMC formulations containing GSNO and SNAC on the surface of the eye. We chose the concentration 1 mM, which was previously shown to have in vitro microbicidal effects against trophozoites of Acanthamoeba castellanii (21) and a concentration ten times higher than this in order to explore the toxicity level of these RSNOs.
The Draize rabbit eye test used in the present study has been globally accepted since 1944 as the standard regulatory method for determining the ocular irritation potential of chemical products (27) (28) (29) (30) . However, its use has been criticized on the bases of ethical considerations since it is employed on live animals. Alternative methods have been discussed for ocular toxicity assessment (30) . Many tests have been published using ex vivo tissue and cell culture of animal and human tissue (27, 30, 31) . Despite good reproducibility and sensitivity of several in vitro alternative model assays for ocular irritation, their predictive power was not as reliable as the rabbit Draize eye test (30) . Moreover, the majority of these tests do not address the issue of ocular irritation reversibility (32) . Ex vivo assays are accepted by regulatory authorities for specific and limited purposes (30) . As recommended by regulatory agencies (27, 30) , in the present study a tiered testing stra tegy was performed to minimize consequential animal distress. It included concerns about the use of neutral formulations and the use of similar NO donors in animal eyes and ocular tissue described in the literature (14, 15) .
Considering that the cornea is an avascular tissue, topical administration is a first choice approach for treating diseases of the anterior segment of the eye such as glaucoma and keratitis (33) . In addition, topical application may allow the use of locally high concentrations of active principles, with minor or non-significant side effects (33) . The HPMC used for the topical instillations of aqueous SNAC and GSNO solutions in this work is a non-toxic hydrophilic mucoadhesive polymer with film forming properties, commonly used in intraocular sur gery, topical administrations, artificial tears and drug vehicle (34, 35) . It is known that tear drainage and blinking action may result in low drug absorption following topical ocular application. This consideration accounts for why HPMC solution was used as a vehicle. It acts as a viscosity enhancer and is expected to increase both the residence time of the S-nitrosothiols in the cul-de-sac and their bioavailability on the pre corneal tear film (36) (37) (38) . Moreover, the low amount of S-nitrosothiols decomposition in the HPMC matrix indicates that this vehicle is appropriate for ocular drug delivery.
Generally, topical drug instillation does not result in the diffusion of the drugs into the vitreous chamber and their pharmacological actions are limited to the anterior ocular surfaces not affecting the retina and the choroid. In fact, Behar-Cohen et al. (14) showed that nitrite levels were undetectable in the rabbit vitreous humor after an NO donor injection into the anterior chamber. The absence of histological alterations and of inflammatory infiltrates observed in our in vivo results is, therefore, consistent with the ex vivo results.
CONCLUSIONS
Aqueous HPMC formulations containing SNAC or GSNO up to 10 mM display low ocular surface toxicity in topical applications and might be a promising option for treating ocular diseases where nitric oxide may have microbicidal or other beneficial pharmaceutical actions.
